These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18431358)

  • 21. Androgen deprivation therapy for prostate cancer.
    Das M
    Lancet Oncol; 2017 Oct; 18(10):e567. PubMed ID: 28870614
    [No Abstract]   [Full Text] [Related]  

  • 22. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved.
    Azvolinsky A
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000
    [No Abstract]   [Full Text] [Related]  

  • 23. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?
    Harrison MR; Jones LW
    Eur Urol; 2014 May; 65(5):873-4. PubMed ID: 24315708
    [No Abstract]   [Full Text] [Related]  

  • 27. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits.
    Oefelein MG
    Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of combined exercise training on indices of obesity, diabetes and cardiovascular risk in type 2 diabetes patients.
    Lambers S; Van Laethem C; Van Acker K; Calders P
    Clin Rehabil; 2008 Jun; 22(6):483-92. PubMed ID: 18511528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.
    Bourke L; Chico TJ; Albertsen PC; Hamdy FC; Rosario DJ
    Heart; 2012 Mar; 98(5):345-8. PubMed ID: 22155645
    [No Abstract]   [Full Text] [Related]  

  • 30. [Quality of life during hormonal therapy for prostate cancer].
    Konaka H; Miwa S; Namiki M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():604-9. PubMed ID: 22208052
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.
    Shah SI; Cafferty FH; Langley RE; Abel PD
    J Sex Med; 2014 Jan; 11(1):314-5. PubMed ID: 24112553
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?
    Roach M
    J Clin Oncol; 2007 Nov; 25(33):5325-6; author reply 5326. PubMed ID: 18024880
    [No Abstract]   [Full Text] [Related]  

  • 34. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body image perceptions in men with prostate cancer.
    Harrington JM; Jones EG; Badger T
    Oncol Nurs Forum; 2009 Mar; 36(2):167-72. PubMed ID: 19273405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
    Levine GN; D'Amico AV; Berger P; Clark PE; Eckel RH; Keating NL; Milani RV; Sagalowsky AI; Smith MR; Zakai N;
    CA Cancer J Clin; 2010; 60(3):194-201. PubMed ID: 20124400
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.